ABSTRACT
OBJECTIVE: Although endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) is the gold standard for diagnosing pancreatic lesions, its negative predictive value is suboptimal. Our aim was to evaluate the yield of contrast-enhanced EUS (CED-EUS) and of strain ratio EUS-elastography (SR-E-EUS) for differentiating pancreatic solid lesions. METHODS: Forty-seven patients (27 men, 20 women, 70 ± 11 years) were consecutively involved in this single-center, prospective study. They were submitted to EUS, SR-E-EUS, CED-EUS with Sonovue(®), and EUS-FNA. The final diagnosis was based on the histological assessment of EUS-FNA and/or surgical specimens when available, and on follow-up of at least 6 months. RESULTS: From the 47 focal pancreatic lesions included, 13 (28%) were benign and 34 (72%) malignant. Patients with malignancy were older (70 ± 11 vs. 61 ± 8, P = 0.003), and had larger lesions (34 ± 12 mm vs. 22 ± 11 mm, P = 0.03). Malignant lesions had higher SR-E-EUS (31 ± 32 vs. 8 ± 9, P = 0.001) and more hypovascular pattern (93% vs. 33%, P < 0.001). Logistic regression determined that only hypovascularity (OR = 2.6, 95%CI: 1.5-130, P = 0.02) was independently predictive of malignancy. ROC analysis for SR-E-EUS yielded an optimal cutoff of 8 (AUC 0.91, 95%CI: 0.74-0.98) for the best power distinction for malignancy. There was no significant difference concerning sensitivity (79%, 90%, 93%) and specificity rates (85%, 75%, 67%) of EUS-FNA, SR-E-EUS, and CED-EUS, respectively. By analysis of the inconclusive EUS-FNA subset (9 patients, 19%), SR-E-EUS > 8 and hypovascularity showed sensitivity of 80% and 100%, and specificity of 67% and 67%, respectively. CONCLUSION: The clinical utility of CED-EUS and SR-E-EUS remains questionable. The accuracies of CED-EUS and SR-E-EUS are similar to EUS-FNA. Hypovascularity was independently predictive of malignancy. Patients with inconclusive EUS-FNA could benefit from CED-EUS due to the high sensitivity of hypovascularity for diagnosing malignancy.
ABSTRACT
UNLABELLED: BACKGROUND/GOAL: Self-expandable metallic stents can be used to reestablish luminal continuity in patients with malignancy of the esophagus, gastric outlet, or colon who are at high risk for surgical intervention. Data regarding their complication profiles remain incomplete. Our aim was to evaluate the feasibility and complications of endoscopic stenting in esophageal, gastroduodenal, and colonic malignancies. STUDY: Between January 2003 and December 2005, 153 patients underwent 182 endoscopic procedures for insertion of 199 metallic stents in a single referral center. Complications were assessed retrospectively. RESULTS: The mean follow-up was 170 days. The mortality was 73.9% (113 patients), 105 cases between 1 and 60 weeks after the procedure (median survival, 17 wk), but none directly related to the stent placement. One single stent was required in 115 (75%) patients, and 37 (24.2%) cases required an overlapping stent. The procedure was unsuccessful in only 1 case of colonic obstruction. Thirty-eight (26.6%) patients developed 52 complications, of which 16 (9.4%) procedure-related complications (perforation, 5; migration, 5; obstruction, 3; misplacement, 2; and hemorrhage, 1) and 36 (21.3%) late complications (obstruction, 20; migration, 9; fistula, 6; and perforation, 1). Eight (5.6%) patients experienced more than 1 complication. Five (3.5%) cases required surgery (colon: 2 perforations, 1 fistula, and 1 obstruction; esophagus: 1 perforation). No significant difference on the complication rates was found for any site in which a metallic stent was inserted. CONCLUSIONS: Endoscopic stenting for palliation of digestive cancer, despite a reasonable complication rate, is feasible in most patients. Most dysfunctions are not life-threatening and can be managed endoscopically.
Subject(s)
Colorectal Neoplasms/surgery , Duodenal Neoplasms/surgery , Esophageal Neoplasms/surgery , Stents/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/mortality , Duodenal Neoplasms/mortality , Endoscopy, Digestive System/adverse effects , Endoscopy, Digestive System/methods , Esophageal Neoplasms/mortality , Female , Follow-Up Studies , Humans , Intestinal Obstruction/etiology , Male , Middle Aged , Palliative Care , Retrospective StudiesABSTRACT
BACKGROUND: Surgery is the traditional treatment for symptomatic pancreatic pseudocysts, but the morbidity is still too high. Minimally invasive endoscopic approaches have been encouraged. AIMS: To evaluate the efficacy of endoscopic ultrasound-guided endoscopic transmural drainage of pancreatic pseudocysts. METHODS: From January, 2003 to August, 2006, 31 consecutive symptomatic patients submitted to 37 procedures at the same endoscopic unit were retrospectively analysed. Chronic and acute pancreatitis were found in, respectively, 17 (54.8%) and 10 (32.3%) cases. Bulging was present in 14 (37.8%) cases. Cystogastrostomy or cystoduodenostomy were created with an interventional linear echoendoscope under endosonographic and fluoroscopic control. By protocol, only a single plastic stent, without nasocystic drain, was used. Straight or double pigtail stents were used in, respectively, 22 (59.5%) and 15 (40.5%) procedures. RESULTS: Endoscopic ultrasound-guided transmural drainage was successful in 29 (93.5%) patients. Two cases needed surgery, both due to procedure-related complications. There was no mortality related to the procedure. Twenty-four patients were followed-up longer than 4 weeks. During a mean follow-up of 12.6 months, there were six (25%) symptomatic recurrences due to stent clogging or migration, with two secondary infections. Median time for developing complications and recurrence of the collections was 3 weeks. These cases were successfully managed with new stents. Complications were more frequent in patients treated with straight stents and in those with a recent episode of acute pancreatitis. CONCLUSIONS: Endoscopic transmural drainage provides an effective approach to the management of pancreatic pseudocysts.
Subject(s)
Drainage/methods , Endosonography/methods , Pancreatic Diseases/surgery , Pancreatic Pseudocyst/surgery , Ultrasonography, Interventional/methods , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Child , Chronic Disease , Drainage/adverse effects , Endosonography/adverse effects , Female , Humans , Male , Middle Aged , Pancreatic Diseases/diagnostic imaging , Pancreatic Pseudocyst/ultrastructure , Retrospective Studies , Treatment Outcome , Ultrasonography, Interventional/adverse effectsABSTRACT
BACKGROUND: Surgery is the traditional treatment for symptomatic pancreatic pseudocysts, but the morbidity is still too high. Minimally invasive endoscopic approaches have been encouraged. AIMS: To evaluate the efficacy of endoscopic ultrasound-guided endoscopic transmural drainage of pancreatic pseudocysts. METHODS: From January, 2003 to August, 2006, 31 consecutive symptomatic patients submitted to 37 procedures at the same endoscopic unit were retrospectively analysed. Chronic and acute pancreatitis were found in, respectively, 17 (54.8 percent) and 10 (32.3 percent) cases. Bulging was present in 14 (37.8 percent) cases. Cystogastrostomy or cystoduodenostomy were created with an interventional linear echoendoscope under endosonographic and fluoroscopic control. By protocol, only a single plastic stent, without nasocystic drain, was used. Straight or double pigtail stents were used in, respectively, 22 (59.5 percent) and 15 (40.5 percent) procedures. RESULTS: Endoscopic ultrasound-guided transmural drainage was successful in 29 (93.5 percent) patients. Two cases needed surgery, both due to procedure-related complications. There was no mortality related to the procedure. Twenty-four patients were followed-up longer than 4 weeks. During a mean follow-up of 12.6 months, there were six (25 percent) symptomatic recurrences due to stent clogging or migration, with two secondary infections. Median time for developing complications and recurrence of the collections was 3 weeks. These cases were successfully managed with new stents. Complications were more frequent in patients treated with straight stents and in those with a recent episode of acute pancreatitis. CONCLUSIONS: Endoscopic transmural drainage provides an effective approach to the management of pancreatic pseudocysts.
RACIONAL: A abordagem cirúrgica é o tratamento tradicional para os pseudocistos sintomáticos de pâncreas, contudo a morbidade permanece elevada. Terapêuticas endoscópicas minimamente invasivas têm sido encorajadas. OBJETIVO: Avaliar a eficácia da drenagem endoscópica transmural de pseudocistos de pâncreas guiada por ecoendoscopia. MÉTODOS: De janeiro de 2003 a agosto de 2006, 31 pacientes sintomáticos submetidos a 37 procedimentos no mesmo centro de referência foram analisados retrospectivamente. Pancreatite crônica e aguda foram detectadas em, respectivamente, 17 (54,8 por cento) e 10 (32,3 por cento) pacientes. Abaulamento da parede esteve presente em 14 (37,8 por cento) casos. Cistogastrostomias ou cistoduodenostomias foram criadas com um ecoendoscópio linear sob controle endosonográfico e fluoroscópico. Como rotina, apenas uma única prótese plástica foi empregada, sem dreno nasocístico. Próteses retas ou " double pigtail" foram empregadas em, respectivamente, 22 (59,5 por cento) e 15 (40,5 por cento) procedimentos. RESULTADOS: A drenagem endoscópica foi adequada em 29 (93,5 por cento) pacientes. Dois casos necessitaram intervenção cirúrgica por complicações do procedimento. Não houve mortalidade relacionada ao procedimento. Vinte e quatro pacientes contaram com seguimento superior a 4 semanas. Durante seguimento médio de 12,6 meses, ocorreram seis (25 por cento) recurrências sintomáticas por obstrução ou migração da prótese, com infecção secundária em dois casos, todos manejados com novas próteses. O tempo mediano para ocorrência de complicações foi de 3 semanas. Complicações tardias foram mais freqüentes em pacientes tratados com próteses retas e naqueles com história recente de pancreatite aguda. CONCLUSÔES: A drenagem endoscópica transmural constitui abordagem efetiva para o manejo dos pseudocistos de pâncreas.